To systematic review the correlation between p21 codon31 polymorphism and cervical cancer. Methods: Literature retrieval was conducted in the databases, such as PubMed, Web of science, Medline, CNKI, WanFang, VIP, and CBM. The relevant articles published in these databases from establishment to August 31st, 2022 were retrieved. Five genetic models were used for meta-analysis, and the odds ratio (OR) value and its 95% CI were used to assess the strength of the correlation between p21 codon31 polymorphism and cervical cancer. Results: A total of 19 literatures of case-control study related to p21 codon31 polymorphism and cervical cancer were included in this meta-analysis, which included 3612 cases in the cervical cancer group and 4135 cases in the control group. The allele model (Arg vs. Ser, I2=80.5%, OR=1.03，95%CI: 0.87-1.21), the homozygous comparison model (Arg/Arg vs. Ser/Ser, I2=71.8%, OR=1.03, 95%CI: 0.76-1.39), the heterozygous model (Ser/Arg vs. Ser/Ser, I2=71.8%, OR=0.96, 95%CI: 0.78-1.17), the dominant model (Arg/Arg+Ser/Arg vs. Ser/Ser, I2=83.8%, OR=0.94, 95%CI: 0.73-1.20), and the recessive model (Arg/Arg vs. Ser/Ser+Ser/Arg, I2=65.2%, OR=1.02, 95%CI: 0.80-1.30) all suggested that the p21 codon31 polymorphism could not increase the risk of hereditary susceptibility of cervical cancer. Further analysis of the classification of cervical cancer found that the p21 codon31 polymorphism had no associated correlation with the cervical squamous cell carcinoma, either. But the homozygous model (Arg/Arg vs. Ser/Ser, I2=48.4%, OR=0.53, 95%CI: 0.32-0.86) and the dominant model (Arg/Arg+Ser/Arg vs. Ser/Ser, I2=0.0, OR=0.61, 95%CI: 043-0.88) suggested that Arg mutant type was a protective factor of the cervical adenocarcinoma. Conclusion: Although the p21 codon31 polymorphism is not associated with cervical cancer or cervical squamous cell carcinoma, it is associated with cervical adenocarcinoma.